Diego Espinosa-Heidmann, MD
Retina Specialist · Augusta, GANPI 1891913380
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $720 and has fallen 52.4% since, to $343 in 2025.
Across 28 payments — averaging $77.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$463
- Astellas Pharma US Inc$421
- Alcon$229
- Oyster Point Pharma, Inc.$150
- Johnson & Johnson Surgical Vision, Inc.$147
- Amgen$136
- plus $611 from 6 others
Across 23 payments — averaging $1426.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$33K
What the payments were for
- Food & beverage$2,157100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 10 | $463 |
| Astellas Pharma US Inc | 4 | $421 |
| Alcon | 2 | $229 |
| Oyster Point Pharma, Inc. | 1 | $150 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $147 |
| Amgen | 2 | $136 |
| Alimera Sciences, Inc. | 3 | $132 |
| Regeneron Healthcare Solutions, Inc. | 1 | $132 |
| AbbVie | 1 | $125 |
| Apellis Pharmaceuticals, Inc. | 1 | $109 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $99 |
| Coherus Oncology, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few retina specialist providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bromfenac Sodium | 28 | $8,168 |
| Brimonidine Tartrate | 63 | $2,271 |
| Prednisolone Acetate | 32 | $1,485 |
| Latanoprost | 102 | $826 |
| Ketorolac Tromethamine | 17 | $791 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 28 | $583 |
| Dorzolamide Hcl | 24 | $349 |
| Timolol Maleate | 21 | $126 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Augusta
- Ranjit DhaliwalAugusta$18K
- Oksana DemediukAugusta$16K
- Sohail KhanAugusta$3K
- Julian NussbaumAugusta$891
- David Chin YeeAtlanta$816K
- Daniel OhAtlanta$58K
- Sruthi ArepalliAtlanta$30K
- Alexander BottiniBraselton$7K
- Kareem SioufiMarietta$6K
- James FrankAtlanta$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.